An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone [moxifloxacin] in the treatment of pulmonary tuberculosis.

Trial Profile

An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone [moxifloxacin] in the treatment of pulmonary tuberculosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Moxifloxacin (Primary) ; Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RIFAQUIN
  • Most Recent Events

    • 06 Mar 2013 Primary endpoint 'Clinical-response-rate' has been met.
    • 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 01 Dec 2012 Last checked against ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top